Clinical trials: Neoplasms, Solid Tumor
Advanced Solid Tumors
Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors
This study will test a Regeneron drug called REGN13089-M404-M2980 ("study drug") to see if it can help treat previously treated, advanced solid tumors (tumors that have grown and spread to different areas of the body).
- Trial name
- NCT07863024
- Testing
- REGN13089-M404-M2980
- Volunteers
- 320 people
- Sponsor
- Regeneron Pharmaceuticals
Solid Tumors
A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors
A phase 1 open-label dose escalation study of OMP-21M18 in subjects with previously treated solid tumour for which there is no remaining standard curative therapy and no therapy with a demonstrated survival benefit.
- Trial name
- NCT00744562
- Testing
- OMP-21M18
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Solid Tumor
Intestinal Microbiome Modification With Resistant Starch in Patients Treated With Dual Immune Checkpoint Inhibitors
This is a pilot study designed to assess the safety and feasibility of administering a dietary supplement to patients undergoing cancer treatment with a dual immune checkpoint inhibitors (ICIs) for solid cancer.
- Trial name
- NCT04552418
- Testing
- Potato starch
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Michigan Rogel Cancer Center
Advanced Cancer, Solid Tumors
Morphine Versus Methadone As First Line Strong Opioid for Cancer Pain
Primary Aims: To determine whether methadone used as first line strong opioid is superior to morphine as evidenced by reduced pain over a 12-week treatment period in patients with advanced cancer.
- Trial name
- NCT00634010
- Testing
- Morphine, Methadone
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
Anhydrovinblastine in Treating Patients With Advanced Recurrent Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of anhydrovinblastine in treating patients who have…
- Trial name
- NCT00003882
- Testing
- anhydrovinblastine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Roswell Park Cancer Institute
Advanced or Metastatic Solid Tumors, FGFR Mutations
Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)
The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumors harboring activating FGFR mutations or…
- Conditions
- Advanced or Metastatic Solid Tumors, FGFR Mutations, FGFR Translocations
- Trial name
- NCT04003623
- Testing
- Pemigatinib
- Where
- 11 sites in United States
- Volunteers
- 1 people
- Sponsor
- Incyte Corporation
Advanced Cancer
A Study of Anti-Lewis Y Chimeric Antigen Receptor-T Cells (LeY-CAR-T) in Patients With Solid Tumours
This clinical trial is an open-label, single-centre, phase I study designed to investigate the safety and tolerability of a single infusion of autologous peripheral blood T-lymphocytes transduced with the anti-LeY-scFv-CD28-ζ…
- Trial name
- LeY-CAR-T (NCT03851146)
- Testing
- LeY CAR T cells
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Advanced Cancer
A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma
WXFL10030390 (WX390) is a novel oral small molecular that inhibits phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) and has demonstrated potent inhibitory effects on multiple human tumor xenografts.
- Trial name
- NCT03730142
- Testing
- WXFL10030390
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Shanghai Jiatan Pharmatech Co., Ltd
Solid Tumor Cancer, Adult Refractory Cancer
Study of GV20-0251 in Participants With Solid Tumor Malignancies
This is a Phase 1 and Phase 2 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
- Conditions
- Solid Tumor Cancer, Adult Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
- Trial name
- NCT07070518
- Testing
- GV20-0251
- Where
- 3 sites in China
- Volunteers
- 350 people
- Sponsor
- GV20 Therapeutics
NSCLC, Ovarian Cancer
Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations
A Phase I Study of LXH254 in Patients With Advanced Solid Tumors That Harbor MAPK Pathway Alterations.
- Conditions
- NSCLC, Ovarian Cancer, Melanoma, Other Solid Tumors
- Trial name
- NCT02607813
- Testing
- LXH254, PDR001
- Where
- 18 sites in United States, Canada and 8 more
- Volunteers
- 142 people
- Sponsor
- Novartis Pharmaceuticals
Non-small-cell Lung Cancer, Mesothelioma
αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells secreting PD-1 nanobodies…
- Trial name
- NCT04489862
- Testing
- αPD1-MSLN-CAR T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Prevalence and Clinical Manifestations of Cannabis Withdrawal in Hospitalized Patients With Hematological Malignancies Undergoing Bone Marrow Transplant (BMT) or Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
This study evaluates the prevalence of cannabis withdrawal and the clinical manifestations of cannabis withdrawal syndrome in patients hospitalized for BMT or CAR-T therapy.
- Trial name
- NCT07594496
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Mayo Clinic
Recurrence of Solid Tumor, Glioblastoma Multiforme
Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)
This is a non-randomized two-part study of MK-4827 given with temozolomide in participants with advanced cancer. In Part A of the study, the dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of MK-4827 when…
- Conditions
- Recurrence of Solid Tumor, Glioblastoma Multiforme, Melanoma
- Trial name
- NCT01294735
- Testing
- MK-4827, Temozolomide
- Volunteers
- 19 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumors
The Clinical Study of SHR-7631 for Injection in Patients With Advanced Solid Tumors
This study is an open-label, phase I clinical trial of SHR-7631 in patients with advanced solid tumors. The whole study is divided into three stages: dose escalation, dose expansion and efficacy expansion.
- Trial name
- NCT06381050
- Testing
- SHR-7631
- Where
- 2 sites in China
- Volunteers
- 76 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Solid Tumor
AMT-116 in Patients With Advanced Solid Tumors
This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-116, in…
- Trial name
- NCT05725291
- Testing
- AMT-116
- Where
- 10 sites in United States, American Samoa and 1 more
- Volunteers
- 80 people
- Sponsor
- Multitude Therapeutics Inc.
Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma
Sorafenib and Bortezomib in Treating Patients With Advanced Cancer
This phase I trial is studying the side effects and best dose of sorafenib and bortezomib in treating patients with advanced cancer.
- Conditions
- Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Stage III Multiple Myeloma, Stage IV Chronic Lymphocytic Leukemia
- Trial name
- NCT00303797
- Testing
- 17-N-allylamino-17-demethoxygeldanamycin/bortezomib, sorafenib tosylate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
This is an open-label, multicenter, dose-escalation, safety, tolerability, pharmacokinetic and pharmacodynamic study in patients with advanced solid tumors.
- Trial name
- NCT01170897
- Testing
- PEGPH20
- Where
- 5 sites in United States
- Volunteers
- 27 people
- Sponsor
- Halozyme Therapeutics
Pulmonary Nodules
A Pilot Study of PET-CT in the Assessment of Pulmonary Nodules in Children With Malignant Solid Tumors
Because the management of children with solid tumors hinges on the extent of disease, it is crucial to identify metastatic sites. Helical chest computed tomography (CT) is the standard method of excluding pulmonary metastases.
- Trial name
- NCT00629460
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- St. Jude Children's Research Hospital
Locally Advanced/Metastatic Solid Tumors
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
The study has consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2). The primary objectives of this study are to evaluate the safety and tolerability of ISM3412 in participants…
- Trial name
- NCT06414460
- Testing
- ISM3412
- Where
- 10 sites in United States, China
- Volunteers
- 146 people
- Sponsor
- InSilico Medicine Hong Kong Limited
Ovarian Cancer, Solid Tumor
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.
- Trial name
- NCT06234423
- Testing
- CUSP06
- Where
- 15 sites in United States, Australia
- Volunteers
- 263 people
- Sponsor
- OnCusp Therapeutics, Inc.
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.